Necrotizing fasciitis

VEGZELMA® (bevacizumab-adcd) receives preferred formulary status with Ventegra® for commercially insured patients

Retrieved on: 
Monday, December 11, 2023
Urine, Reproduction, Skeleton, Headache, PSA, Kidney, Erythroderma, Patient, Pharmacy, Birth, Nephrotic syndrome, MBA, Cancer, Miscarriage, Safety, Incidence, VTE, Bevacizumab, Corneal opacity, Wound healing, VEGFR2, Gastrointestinal perforation, Hemoptysis, Female, Fetus, CHF, Celltrion, Pharming, Necrotizing fasciitis, Heart failure, Fistula, Risk, Tracheoesophageal fistula, Bleeding, Organogenesis, Partnership, Rhinitis, Hypertension, Primary ovarian insufficiency, Back pain, Pregnancy, Glioblastoma, PRES, Nosebleed, Skull, FDA, ATE, VEGF, MBM, Hypertensive encephalopathy, Toxicity, Nursing, Pharmaceutical industry, Birth control, Dietary supplement, Proteinuria

Ventegra's proprietary formulary program (which includes Formulary Shield and the Ventegra Specialty Inclusion Program) is available for access by more than 400 clients and 13 million members/patients that are enrolled with Ventegra.

Key Points: 
  • Ventegra's proprietary formulary program (which includes Formulary Shield and the Ventegra Specialty Inclusion Program) is available for access by more than 400 clients and 13 million members/patients that are enrolled with Ventegra.
  • Gastrointestinal Perforations and Fistula: Discontinue for gastrointestinal perforations, tracheoesophageal fistula, grade 4 fistula, or fistula formation involving any organ.
  • Surgery and Wound Healing Complications: In patients who experience wound healing complications during VEGZELMA treatment, withhold VEGZELMA until adequate wound healing.
  • Do not administer VEGZELMA for at least 28 days following a major surgery, and until adequate wound healing.

Flesh-eating bacteria infections are on the rise in the US − a microbiologist explains how to protect yourself

Retrieved on: 
Monday, September 25, 2023
People, Infection, Tissue, Shellfish, Disease, Climate, Diabetes, Amputation, HIV, Necrotizing fasciitis, Liver disease, Indiana University School of Medicine, Sore, Fever, Cancer, Immunity, Seafood, Wound, CDC, Blood, Swimming, Eating, Streptococcus, Swelling, Time, Vibrio vulnificus, Water, Korea Disease Control and Prevention Agency, Cyclone, Blister, Center, Bacteria, Ulcer, Climate change, Skin discoloration, Red, Skin, Microbiology, Vaccine, Oyster farming, Vibrio

Flesh-eating bacteria sounds like the premise of a bad horror movie, but it’s a growing – and potentially fatal – threat to people.

Key Points: 
  • Flesh-eating bacteria sounds like the premise of a bad horror movie, but it’s a growing – and potentially fatal – threat to people.
  • In September 2023, the Centers for Disease Control and Prevention issued a health advisory alerting doctors and public health officials of an increase in flesh-eating bacteria cases that can cause serious wound infections.

What does ‘flesh-eating’ mean?

    • There are several types of bacteria that can infect open wounds and cause a rare condition called necrotizing fasciitis.
    • These bacteria do not merely damage the surface of the skin – they release toxins that destroy the underlying tissue, including muscles, nerves and blood vessels.
    • The bacterial species group A Streptococcus, or group A strep, is the most common culprit behind necrotizing fasciitis.

How do you catch flesh-eating bacteria?

    • Most infections in the U.S. occur in the warmer months, between May and October.
    • People who swim, fish or wade in these bodies of water can contract the bacteria through an open wound or sore.
    • Vibrio vulnificus can also get into seafood harvested from these waters, especially shellfish like oysters.

Why are flesh-eating bacteria infections rising?

    • But rising ocean temperatures due to global warming are creating new habitats for this type of bacteria, which can now be found along the East Coast as far north as New York and Connecticut.
    • A recent study noted that Vibrio vulnificus wound infections increased eightfold between 1988 and 2018 in the eastern U.S.
    • Climate change is also fueling stronger hurricanes and storm surges, which have been associated with spikes in flesh-eating bacteria infection cases.

What are symptoms of necrotizing fasciitis? How is it treated?

    • Early symptoms of an infected wound include fever, redness, intense pain or swelling at the site of injury.
    • If you have these symptoms, seek medical attention without delay.
    • Necrotizing fasciitis can progress quickly, producing ulcers, blisters, skin discoloration and pus.

How do I protect myself?

    • People who have a fresh cut, including a new piercing or tattoo, are advised to stay out of water that could be home to Vibrio vulnificus.
    • Wounds that occur while fishing, preparing seafood or swimming should be washed immediately and thoroughly with soap and water.
    • This includes people taking immunosuppressive medications or those who have pre-existing conditions such as liver disease, cancer, HIV or diabetes.

TheracosBio and SmithRx Collaborate to Offer Newly Approved Diabetes Drug Brenzavvy™ (bexagliflozin) to Members with Type 2 Diabetes

Retrieved on: 
Thursday, August 17, 2023
Software, Biotechnology, Pharmaceutical, Health, Diabetes, Data Management, Health Technology, Technology, Diabetic neuropathy, Type 2 diabetes, Tenderness, Glycosuria, Dialysis, Gangrene, Pain, Urinary tract infection, 1946 Antarctica PBM Mariner crash, Incidence, Patient, Risk, PBM, Insulin, Ulcer, Pancreatitis, Diet, Cardiovascular disease, Urination, Vomiting, Cost Plus Drugs, Hypoglycemia, FDA, Death, Exercise, World Market (store), Chronic kidney disease, Amputation, Creatinine, Hypotension, Dehydration, Metabolic acidosis, Fever, CVD, Osteomyelitis, History, Abdominal pain, Ischemia, Erythema, Swelling, Type, Moyamoya disease, Knee, Infection, Pyelonephritis, Elijah Cummings Lower Drug Costs Now Act, Partnership, Hospital, Necrotizing fasciitis, Diabetic ketoacidosis, Pharmacy, Perineum, SGLT2, Ketoacidosis, Acute kidney injury, Frenz, Nausea, Female, Pharmaceutical industry, Dietary supplement, Medical imaging, Meat

Working with TheracosBio and Cost Plus Drugs, SmithRx now provides BRENZAVVY as an option following its launch in July 2023.

Key Points: 
  • Working with TheracosBio and Cost Plus Drugs, SmithRx now provides BRENZAVVY as an option following its launch in July 2023.
  • BRENZAVVY is not recommended for use to improve glycemic control in patients with type 1 diabetes mellitus.
  • Diabetes is the most expensive chronic condition in the U.S. and accounts for 1 of every 4 dollars spent on healthcare.
  • In patients with type 1 diabetes mellitus, BRENZAVVY significantly increases the risk of diabetic ketoacidosis, a life-threatening event, beyond background rate.

Recce Pharmaceuticals Provides Positive Update on Patients Treated with RECCE® 327 Under “Special Access Scheme”

Retrieved on: 
Thursday, August 10, 2023
Infection, Male, Multiple drug resistance, Human, Plantar fasciitis, Diabetes, S. aureus, Necrotizing fasciitis, Disclosure, MRSA, Recce, Type 2 diabetes, Therapeutic Goods Administration, Hope, ASX, FSE, Skin, Burn, Osteomyelitis, Confidentiality, Staphylococcus aureus, SAS, Stinger, Wound healing, Death, Patient, Length of stay, Swelling, Disease, Peripheral neuropathy, Fungal infection, Genetically modified bacteria, Mortality, TGA, Methicillin-resistant Staphylococcus aureus, Red, Gram-negative bacteria, Safety, RCE, Moyamoya disease, Pharmaceutical industry, Vaccine

“Antibiotic resistance is globally recognized as one of the greatest threats to human health today,” said James Graham, Chief Executive Officer of Recce Pharmaceuticals.

Key Points: 
  • “Antibiotic resistance is globally recognized as one of the greatest threats to human health today,” said James Graham, Chief Executive Officer of Recce Pharmaceuticals.
  • “To see Recce making a difference for patients in such great medical need is a significant sign of new hope in the fight against drug-resistant superbugs.
  • Upon applying R327G, the initial redness and swelling had minimized after seven days, with the wound healing and drying up.
  • Surgical intervention was averted, such as limb amputation, which is common in patients with diabetes.

TheracosBio Announces Commercial Availability of Brenzavvy™ (bexagliflozin) for the Treatment of Adults with Type 2 Diabetes

Retrieved on: 
Thursday, July 13, 2023
Health, Diabetes, Research, Pharmaceutical, Science, Biotechnology, Diabetic neuropathy, Type 2 diabetes, Tenderness, Dialysis, Gangrene, Pain, Urinary tract infection, A1C, Incidence, Patient, Risk, Insulin, Ulcer, Fasting, Pancreatitis, Diet, Urine, PBC, Cardiovascular disease, Urination, Vomiting, Cost Plus Drugs, Hypoglycemia, FDA, Death, Exercise, DPP4, Chronic kidney disease, Amputation, Creatinine, Hypotension, Dehydration, Metabolic acidosis, Fever, EGFR, CVD, Osteomyelitis, History, Abdominal pain, Ischemia, Blood, Erythema, Metformin, Swelling, Type, Moyamoya disease, Knee, Blood pressure, Medicine, Infection, Pyelonephritis, Food, Hospital, Fatal, Necrotizing fasciitis, Glomerular filtration rate, Diabetic ketoacidosis, Perineum, Calorie, SGLT2, Ketoacidosis, Acute kidney injury, Nausea, Bexagliflozin, Female, Pharmaceutical industry, Dietary supplement, Meat

BRENZAVVY is not recommended for patients with type 1 diabetes mellitus and may increase the risk of diabetic ketoacidosis in these patients.

Key Points: 
  • BRENZAVVY is not recommended for patients with type 1 diabetes mellitus and may increase the risk of diabetic ketoacidosis in these patients.
  • BRENZAVVY treatment can be initiated in adults with type 2 diabetes with an estimated glomerular filtration rate (eGFR) greater than or equal to 30 mL/min/1.73 m2.
  • "We are excited to offer Brenzavvy to our patients with diabetes," said Mark Cuban, co-founder of Mark Cuban Cost Plus Drug Company.
  • "TheracosBio is breaking new ground by making this product available to consumers at a transparent, low price.

CūtisCare Launches Third Annual Hyperbaric Aware™ National Campaign To Elevate Awareness Of Hyperbaric Oxygen Therapy

Retrieved on: 
Monday, May 1, 2023
Osteoradionecrosis, Medicine, Undersea and Hyperbaric Medical Society, Diabetes, Amputation, HBOT, Necrotizing fasciitis, Underwater environment, BOCA, Quality of life, Research, Gangrene, Hyperbaric medicine, Patient, Physician, Center of excellence, Actinomycosis, Pharmaceutical industry, Hospital

BOCA RATON, Fla., May 1, 2023 /PRNewswire/ -- Hyperbaric Awareness USA™, a CutisCare initiative, has designated May Hyperbaric Awareness Month and is proud to announce the launch of the third annual Hyperbaric Aware™ national campaign to elevate awareness of hyperbaric oxygen therapy (HBOT).

Key Points: 
  • BOCA RATON, Fla., May 1, 2023 /PRNewswire/ -- Hyperbaric Awareness USA™, a CutisCare initiative, has designated May Hyperbaric Awareness Month and is proud to announce the launch of the third annual Hyperbaric Aware™ national campaign to elevate awareness of hyperbaric oxygen therapy (HBOT).
  • CutisCare launches a Hyperbaric Awareness USA campaign to elevate the awareness of hyperbaric oxygen therapy.
  • (HBOT)
    The Hyperbaric Aware website, HyperbaricAware.com , in collaboration with the Undersea and Hyperbaric Medical Society (UHMS) and physician leaders, has resources available for both patients and physicians alike.
  • Help us spread the word this May about the many benefits of Hyperbaric Oxygen Treatment!

Bioventus TheraSkin Coverage Expands to Provide for 17 Million More Covered Lives

Retrieved on: 
Friday, April 8, 2022
Innovation, Company, LinkedIn, RCT, Radiation, Patient, Skin, Necrotizing fasciitis, Sal DiDomenico, Standard of care, Tissue, PMID, Evidence-based medicine, LLC, Twitter, Nasdaq, Joint capsule, GLOBE, Physician, Medicare, NEXUS, FDA, Wound healing, Pharmaceutical industry

Bioventus TheraSkin is a cellular and tissue-based treatment for difficult to heal chronic wounds and this expanded coverage adds more than 17 million medical lives to the existing coverage.

Key Points: 
  • Bioventus TheraSkin is a cellular and tissue-based treatment for difficult to heal chronic wounds and this expanded coverage adds more than 17 million medical lives to the existing coverage.
  • This recent publication further supplements the 13 previous published articles supporting wound treatment with TheraSkin.
  • Bioventus and the Bioventus logo, are registered trademarks of Bioventus LLC.
  • BoneScalpel, SonaStar, SonicOne and neXus are registered trademarks of Misonix, Inc. TheraSkin is a registered trademark of Soluble Systems, LLC.

US FDA approves Jardiance® (empagliflozin) to treat adults with heart failure regardless of left ventricular ejection fraction

Retrieved on: 
Thursday, February 24, 2022
Risk, Rash, Breast milk, Animal, Pancreatitis, Diabetes, Company, Facebook, CA, Animal Health, Woman, Type 2 diabetes, Private Securities Litigation Reform Act, Insulin, Research, Genetically modified bacteria, U.S. Securities and Exchange Commission, Vaginal yeast infection, Partnership, Human, Perineum, Boehringer Ingelheim Animal Health, Man, Form 10-K, Fever, Disease, Skin, Quality of life, Corporate social responsibility, Boehringer Ingelheim, D, Twitter, Pain, Health, Pancreas, Kidney, Allergy, Heart failure, Swelling, Hypersensitivity, Eli Lilly and Company, Hospital, Vitamin, Patient, Tenderness, Candidiasis, Death, Penis, Chronic kidney disease, Heart, Erythema, Vagina, Necrotizing fasciitis, Cardiovascular disease, Birth control, Health insurance, Pharmaceutical industry, Fine chemical, Lilly

This bacterial infection has happened in women and men who take JARDIANCE, and may lead to hospitalization, multiple surgeries, and death.

Key Points: 
  • This bacterial infection has happened in women and men who take JARDIANCE, and may lead to hospitalization, multiple surgeries, and death.
  • Swelling of an uncircumcised penis may develop that makes it difficult to pull back the skin around the tip of the penis.
  • Talk to your healthcare provider about what to do if you get symptoms of a yeast infection of the vagina or penis.
  • Talk to your healthcare provider right away if you use an over-the-counter antifungal medication and your symptoms do not go away.

US FDA accepts supplemental New Drug Application and grants Priority Review for Jardiance® for adults with heart failure independent of left ventricular ejection fraction

Retrieved on: 
Thursday, November 11, 2021
Corporate social responsibility, Swelling, Boehringer Ingelheim, D, Animal Health, Vitamin, Pain, Risk, Erythema, Hypersensitivity, Tenderness, Candidiasis, Type 2 diabetes, Kidney, Genetically modified bacteria, Health, Pancreatitis, Research, Facebook, Woman, Hospital, Fever, Red, Patient, Quality of life, Private Securities Litigation Reform Act, U.S. Securities and Exchange Commission, Heart, Necrotizing fasciitis, Disease, Rash, Vagina, Boehringer Ingelheim Animal Health, Chronic kidney disease, Breast milk, Animal, Human, Twitter, Man, CA, Insulin, Partnership, Form 10-K, Eli Lilly and Company, Company, Heart failure, Death, Pancreas, Diabetes, Skin, Drug development, Penis, Birth control, Health insurance, Pharmaceutical industry, Fine chemical

Talk to your healthcare provider right away if you use an over-the-counter antifungal medication and your symptoms do not go away.

Key Points: 
  • Talk to your healthcare provider right away if you use an over-the-counter antifungal medication and your symptoms do not go away.
  • Before taking JARDIANCE, tellyourhealthcare providerabout all of your medical conditions, including ifyou:
    are going to have surgery.
  • Tell your healthcare provider right away if you become pregnant during treatment with JARDIANCE
    are breastfeeding or are planning to breastfeed.
  • However, as with any pharmaceutical product, there are substantial risks and uncertainties in the process of drug development and commercialization.

FDA grants Jardiance® Breakthrough Therapy designation for heart failure with preserved ejection fraction

Retrieved on: 
Thursday, September 9, 2021

Talk to your healthcare provider right away if you use an over-the-counter antifungal medication and your symptoms do not go away.

Key Points: 
  • Talk to your healthcare provider right away if you use an over-the-counter antifungal medication and your symptoms do not go away.
  • Allergic (hypersensitivity) reactions.Symptomsofseriousallergicreactionsto JARDIANCE mayinclude:
    If you have anyof these symptoms,stoptakingJARDIANCEandcontactyourhealthcare providerorgo to the nearestemergencyroomrightaway.
  • Before taking JARDIANCE, tellyourhealthcare providerabout all of your medical conditions, including ifyou:
    are going to have surgery.
  • Clinical trials have been initiated to evaluate the impact of Jardiance on people living with heart failure or chronic kidney disease.